IR InformationNotice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026–FY2028)
IR InformationPresentation Material for Management Presentation on Feb 27th 2026
IR InformationNotice of Commencement of Consideration of Spin-off of Styrene-Related Businesses
IR InformationFY2025 Third Quarter Financial Results Presentation Summary of Q&A Session
IR InformationFY2025 Third Quarter Financial Results Presentation Materials with Script
IR InformationNotice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)
IR InformationNotice Regarding Recognition of Extraordinary Losses
IR InformationNotice Regarding Personnel Changes in Executive Officers
IR InformationFY2025 Third Quarter Financial Results Presentation Materials
IR InformationFY2025 Third Quarter Summary of Consolidated Financial Results
NewsAwarded “A-” for Climate Change and “A” rating for Water Security in CDP 2025
NewsDevelopment of an ESD (endoscopic submucosal dissection) simulator model for early-stage gastrointestinal neoplasms~Results of the third “Medical Rising STAR” industry-academia collaboration project~
NewsPresident's New Year's address (excerpt from New Year's speech)
This website uses cookies to ensure that you use this website comfortably. If you continue to browse this website, you will agree to the use of our cookies.